Ignite Planners LLC Sells 19,169 Shares of Edwards Lifesciences Corporation $EW

Ignite Planners LLC lowered its position in Edwards Lifesciences Corporation (NYSE:EW) by 64.7% in the 2nd quarter, HoldingsChannel reports. The fund owned 10,441 shares of the medical research company’s stock after selling 19,169 shares during the period. Ignite Planners LLC’s holdings in Edwards Lifesciences were worth $799,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in EW. Nuveen LLC bought a new position in Edwards Lifesciences during the first quarter worth about $330,881,000. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Mirova US LLC lifted its stake in shares of Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after buying an additional 1,054,301 shares in the last quarter. Woodline Partners LP boosted its holdings in Edwards Lifesciences by 7,805.0% in the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after buying an additional 814,917 shares during the period. Finally, AQR Capital Management LLC grew its stake in Edwards Lifesciences by 339.7% in the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after buying an additional 709,648 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

NYSE:EW opened at $86.17 on Friday. Edwards Lifesciences Corporation has a 52-week low of $65.31 and a 52-week high of $87.21. The stock has a fifty day moving average of $78.09 and a 200 day moving average of $77.65. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $50.00 billion, a price-to-earnings ratio of 12.40, a P/E/G ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 22,970 shares of company stock worth $1,862,878 over the last three months. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on EW. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research report on Friday, July 25th. Canaccord Genuity Group reiterated a “hold” rating and set a $84.00 price objective (up from $81.00) on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Mizuho increased their price objective on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company lifted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.